vs
Apellis Pharmaceuticals, Inc.（APLS）与LINDSAY CORP（LNN）财务数据对比。点击上方公司名可切换其他公司
Apellis Pharmaceuticals, Inc.的季度营收约是LINDSAY CORP的1.3倍（$199.9M vs $150.7M），LINDSAY CORP净利率更高（11.0% vs -29.5%，领先40.5%），Apellis Pharmaceuticals, Inc.同比增速更快（-5.9% vs -6.1%），Apellis Pharmaceuticals, Inc.自由现金流更多（$-14.3M vs $-15.1M），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs 1.3%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
林赛公司总部位于美国内布拉斯加州奥马哈市，原名林赛制造公司，核心产品为旗下Zimmatic品牌中心枢轴灌溉系统，此外还生产农业机械、工程机械，以及公路与铁路基础设施设备。
APLS vs LNN — 直观对比
营收规模更大
APLS
是对方的1.3倍
$150.7M
营收增速更快
APLS
高出0.2%
-6.1%
净利率更高
LNN
高出40.5%
-29.5%
自由现金流更多
APLS
多$789.0K
$-15.1M
两年增速更快
APLS
近两年复合增速
1.3%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $150.7M |
| 净利润 | $-59.0M | $16.5M |
| 毛利率 | — | 33.3% |
| 营业利润率 | -25.6% | 13.0% |
| 净利率 | -29.5% | 11.0% |
| 营收同比 | -5.9% | -6.1% |
| 净利润同比 | -62.2% | -3.7% |
| 每股收益（稀释后） | $-0.40 | $1.54 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSLNN
| Q4 25 | $199.9M | $150.7M | ||
| Q3 25 | $458.6M | $149.0M | ||
| Q2 25 | $178.5M | $165.7M | ||
| Q1 25 | $166.8M | $183.8M | ||
| Q4 24 | $212.5M | $160.5M | ||
| Q3 24 | $196.8M | $149.4M | ||
| Q2 24 | $199.7M | $133.7M | ||
| Q1 24 | $172.3M | $146.8M |
净利润APLSLNN
| Q4 25 | $-59.0M | $16.5M | ||
| Q3 25 | $215.7M | $10.8M | ||
| Q2 25 | $-42.2M | $19.5M | ||
| Q1 25 | $-92.2M | $26.6M | ||
| Q4 24 | $-36.4M | $17.2M | ||
| Q3 24 | $-57.4M | $12.7M | ||
| Q2 24 | $-37.7M | $20.4M | ||
| Q1 24 | $-66.4M | $18.1M |
毛利率APLSLNN
| Q4 25 | — | 33.3% | ||
| Q3 25 | — | 30.0% | ||
| Q2 25 | — | 32.4% | ||
| Q1 25 | — | 34.0% | ||
| Q4 24 | — | 31.1% | ||
| Q3 24 | — | 30.6% | ||
| Q2 24 | — | 34.8% | ||
| Q1 24 | — | 33.3% |
营业利润率APLSLNN
| Q4 25 | -25.6% | 13.0% | ||
| Q3 25 | 48.7% | 7.6% | ||
| Q2 25 | -18.6% | 14.4% | ||
| Q1 25 | -50.0% | 17.5% | ||
| Q4 24 | -12.3% | 13.0% | ||
| Q3 24 | -24.0% | 9.0% | ||
| Q2 24 | -14.7% | 14.9% | ||
| Q1 24 | -36.0% | 15.1% |
净利率APLSLNN
| Q4 25 | -29.5% | 11.0% | ||
| Q3 25 | 47.0% | 7.3% | ||
| Q2 25 | -23.6% | 11.8% | ||
| Q1 25 | -55.3% | 14.5% | ||
| Q4 24 | -17.1% | 10.7% | ||
| Q3 24 | -29.2% | 8.5% | ||
| Q2 24 | -18.9% | 15.2% | ||
| Q1 24 | -38.5% | 12.3% |
每股收益（稀释后）APLSLNN
| Q4 25 | $-0.40 | $1.54 | ||
| Q3 25 | $1.67 | $0.99 | ||
| Q2 25 | $-0.33 | $1.78 | ||
| Q1 25 | $-0.74 | $2.44 | ||
| Q4 24 | $-0.30 | $1.57 | ||
| Q3 24 | $-0.46 | $1.16 | ||
| Q2 24 | $-0.30 | $1.85 | ||
| Q1 24 | $-0.54 | $1.64 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $199.6M |
| 总债务越低越好 | — | $115.2M |
| 股东权益账面价值 | $370.1M | $518.2M |
| 总资产 | $1.1B | $828.4M |
| 负债/权益比越低杠杆越低 | — | 0.22× |
8季度趋势，按日历期对齐
现金及短期投资APLSLNN
| Q4 25 | $466.2M | $199.6M | ||
| Q3 25 | $479.2M | $250.6M | ||
| Q2 25 | $370.0M | $210.8M | ||
| Q1 25 | $358.4M | $186.7M | ||
| Q4 24 | $411.3M | $194.1M | ||
| Q3 24 | $396.9M | $190.9M | ||
| Q2 24 | $360.1M | $152.7M | ||
| Q1 24 | $325.9M | $150.6M |
总债务APLSLNN
| Q4 25 | — | $115.2M | ||
| Q3 25 | — | $115.3M | ||
| Q2 25 | — | $115.3M | ||
| Q1 25 | — | $115.4M | ||
| Q4 24 | — | $115.4M | ||
| Q3 24 | — | $115.5M | ||
| Q2 24 | — | $115.5M | ||
| Q1 24 | $93.1M | $115.6M |
股东权益APLSLNN
| Q4 25 | $370.1M | $518.2M | ||
| Q3 25 | $401.2M | $532.9M | ||
| Q2 25 | $156.3M | $528.8M | ||
| Q1 25 | $164.2M | $516.4M | ||
| Q4 24 | $228.5M | $488.5M | ||
| Q3 24 | $237.1M | $480.9M | ||
| Q2 24 | $264.3M | $480.0M | ||
| Q1 24 | $266.7M | $483.0M |
总资产APLSLNN
| Q4 25 | $1.1B | $828.4M | ||
| Q3 25 | $1.1B | $840.8M | ||
| Q2 25 | $821.4M | $840.9M | ||
| Q1 25 | $807.3M | $814.2M | ||
| Q4 24 | $885.1M | $771.0M | ||
| Q3 24 | $901.9M | $760.2M | ||
| Q2 24 | $904.5M | $758.1M | ||
| Q1 24 | $831.9M | $765.3M |
负债/权益比APLSLNN
| Q4 25 | — | 0.22× | ||
| Q3 25 | — | 0.22× | ||
| Q2 25 | — | 0.22× | ||
| Q1 25 | — | 0.22× | ||
| Q4 24 | — | 0.24× | ||
| Q3 24 | — | 0.24× | ||
| Q2 24 | — | 0.24× | ||
| Q1 24 | 0.35× | 0.24× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $-597.0K |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $-15.1M |
| 自由现金流率自由现金流/营收 | -7.1% | -10.0% |
| 资本支出强度资本支出/营收 | 0.1% | 9.6% |
| 现金转化率经营现金流/净利润 | — | -0.04× |
| 过去12个月自由现金流最近4个季度 | $45.0M | $62.9M |
8季度趋势，按日历期对齐
经营现金流APLSLNN
| Q4 25 | $-14.2M | $-597.0K | ||
| Q3 25 | $108.5M | $64.0M | ||
| Q2 25 | $4.4M | $35.0M | ||
| Q1 25 | $-53.4M | $12.3M | ||
| Q4 24 | $19.4M | $21.6M | ||
| Q3 24 | $34.1M | $53.1M | ||
| Q2 24 | $-8.3M | $30.5M | ||
| Q1 24 | $-133.0M | $-9.7M |
自由现金流APLSLNN
| Q4 25 | $-14.3M | $-15.1M | ||
| Q3 25 | $108.3M | $49.8M | ||
| Q2 25 | $4.4M | $25.7M | ||
| Q1 25 | $-53.4M | $2.5M | ||
| Q4 24 | $19.3M | $12.5M | ||
| Q3 24 | — | $47.7M | ||
| Q2 24 | $-8.4M | $25.8M | ||
| Q1 24 | $-133.3M | $-21.6M |
自由现金流率APLSLNN
| Q4 25 | -7.1% | -10.0% | ||
| Q3 25 | 23.6% | 33.4% | ||
| Q2 25 | 2.5% | 15.5% | ||
| Q1 25 | -32.0% | 1.4% | ||
| Q4 24 | 9.1% | 7.8% | ||
| Q3 24 | — | 31.9% | ||
| Q2 24 | -4.2% | 19.3% | ||
| Q1 24 | -77.3% | -14.7% |
资本支出强度APLSLNN
| Q4 25 | 0.1% | 9.6% | ||
| Q3 25 | 0.0% | 9.6% | ||
| Q2 25 | 0.0% | 5.6% | ||
| Q1 25 | 0.0% | 5.3% | ||
| Q4 24 | 0.0% | 5.7% | ||
| Q3 24 | 0.0% | 3.6% | ||
| Q2 24 | 0.0% | 3.6% | ||
| Q1 24 | 0.2% | 8.1% |
现金转化率APLSLNN
| Q4 25 | — | -0.04× | ||
| Q3 25 | 0.50× | 5.92× | ||
| Q2 25 | — | 1.79× | ||
| Q1 25 | — | 0.46× | ||
| Q4 24 | — | 1.26× | ||
| Q3 24 | — | 4.17× | ||
| Q2 24 | — | 1.50× | ||
| Q1 24 | — | -0.54× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
LNN
| Transferred At Point In Time | $133.2M | 88% |
| Infrastructure | $13.4M | 9% |
| Transferred Over Time | $8.0M | 5% |
